Amer Sports (United States)

Introduction: Acute coronary syndrome is increasingly affecting the aging population. Despite this, we have observed that older patients presenting with acute coronary syndromes often experience poorer outcomes in the setting of age-related comorbidities and undergo decreased rates of reperfusion therapy. In this analysis, we aimed to uncover any sex differences in outcomes amongst older female patients admitted with ST-Elevation Myocardial Infarction (STEMI). Methods: We utilized the National Inpatient Sample data from 2020 to isolate cases where patients were primarily admitted for STEMI. From this pool, we then identified two subsets: individuals who were aged 65 and over and females. We implemented both logistic and linear regression analyses and accounted for any potential confounding factors. We considered our findings to be statistically significant if the 2-tailed p-value was <0.05. Results: During 2020, there were a total of 159,890 hospitalizations for STEMI. Among these cases, 46.3% or 74,013 involved patients over 65 years old. After adjusting for various factors such as race, hospital characteristics (including bed size, location, and teaching status), insurance coverage, income level, and Elixhauser comorbidities, we noted a number of significant findings for women over the age of 65 admitted due to STEMI. These included a heightened in-hospital mortality rate (aOR 1.36, 95% CI 1.23- 1.52), reduced usage of mechanical ventilation (aOR 0.86, 95% CI 0.78 - 0.96), less likelihood to receive mechanical circulatory support (aOR 0.64, 95% CI 0.53 - 0.78), and a decreased probability to undergo PCI (aOR 0.87, 95% CI 0.81 - 0.94). Conclusion: In hospital admissions for STEMI, we observed that older female patients experienced increased complications during hospitalization and were less likely to undergo invasive reperfusion therapy. Additional research would be required to identify if these sex differences can be attributed to variations in initial presentation before STEMI or if changes in clinical management by sex are contributing to adverse outcomes.

To support social activities of the post-pandemic, some social and creative hubs in Malaysia have emerged with more positive vibes that may revitalise the community. With these third places revival, there is still a lack of study on what has changed for the design of third places in response to the recent Covid-19 crisis. Therefore, this study aims to examine the design of two social and creative hubs in Kuala Lumpur based on the adaptation of Ray Oldenburg's theory of third places. The research objective is to ascertain the third places' characteristics of the case studies through on-site observation.

Oral semaglutide (sema), the first GLP-1 receptor agonist in a tablet formulation, is in late-stage development for the treatment of T2D. The effect and safety of oral sema (3, 7, or 14 mg once daily) was assessed in this randomized, double-blind, placebo-controlled phase 3a trial in drug-naïve patients with T2D uncontrolled on diet and exercise (n=703). Primary endpoint was change from baseline in HbA1c at week 26. The primary estimand (treatment policy) evaluated the effect regardless of trial product discontinuation or rescue medication use (effectiveness). A secondary estimand (hypothetical) evaluated the effect of trial product while on treatment without rescue medication (efficacy) using a mixed model for repeated measures (MMRM), and is the method used in many previous T2D studies. Oral sema resulted in clinically meaningful reductions in both HbA1c (all doses) and body weight (higher doses) at week 26 (Table). Adverse events (AEs) occurred in 58, 53 and 57% for 3, 7 and 14 mg oral sema, respectively, and 56% with placebo. The most common AE with oral sema was transient mild or moderate nausea. Nausea occurred in 5-16% of patients with oral sema vs. 6% with placebo. Oral sema demonstrated superiority vs. placebo in reducing HbA1c (all dose levels) and body weight (14 mg) and was well tolerated in T2D uncontrolled on diet and exercise (ClinicalTrials.gov NCT02906930). Disclosure V.R. Aroda: Consultant; Self; Novo Nordisk Inc.. Research Support; Self; Novo Nordisk Inc., AstraZeneca, Calibra Medical, Eisai Inc., Sanofi. Consultant; Self; Sanofi. Research Support; Self; Theracos, Inc.. Employee; Spouse/Partner; Merck & Co., Inc.. Other Relationship; Self; American Diabetes Association. Consultant; Self; ADOCIA. J. Rosenstock: Advisory Panel; Self; Eli Lilly and Company. Consultant; Self; Eli Lilly and Company. Research Support; Self; Novo Nordisk Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; Sanofi. Consultant; Self; Sanofi. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Intarcia Therapeutics, Inc.. Consultant; Self; Intarcia Therapeutics, Inc.. Research Support; Self; Merck & Co., Inc., Pfizer Inc., Sanofi, Novo Nordisk Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Intarcia Therapeutics, Inc., Genentech, Inc. Y. Terauchi: Research Support; Self; MSD K.K.. Speaker's Bureau; Self; MSD K.K.. Advisory Panel; Self; MSD K.K.. Research Support; Self; Ono Pharmaceutical Co., Ltd.. Speaker's Bureau; Self; Ono Pharmaceutical Co., Ltd.. Research Support; Self; Novartis Pharma K.K., Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH. Research Support; Self; Mitsubishi Tanabe Pharma Corporation. Speaker's Bureau; Self; Mitsubishi Tanabe Pharma Corporation. Advisory Panel; Self; Mitsubishi Tanabe Pharma Corporation. Research Support; Self; Daiichi Sankyo Company, Limited. Speaker's Bureau; Self; Daiichi Sankyo Company, Limited. Advisory Panel; Self; Daiichi Sankyo Company, Limited. Research Support; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Speaker's Bureau; Self; Sanwa Kagaku Kenkyusho Co., Ltd.. Research Support; Self; Novo Nordisk Inc.. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc.. Research Support; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Eli Lilly and Company. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Advisory Panel; Self; Sanofi. Research Support; Self; Sumitomo Dainippon Pharma Co., Ltd.. Speaker's Bureau; Self; Sumitomo Dainippon Pharma Co., Ltd.. Research Support; Self; Shionogi & Co., Ltd.. Speaker's Bureau; Self; Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., Astellas Pharma US, Inc., AstraZeneca. Advisory Panel; Self; AstraZeneca, Teijin Pharma Limited. O. Jeppesen: Employee; Self; Novo Nordisk A/S. Employee; Spouse/Partner; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. E. Christiansen: Stock/Shareholder; Self; Novo Nordisk A/S. Employee; Self; Novo Nordisk A/S. C.L. Hertz: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. M. Haluzik: None.

Public debate on the temporary employment services, or labour broker, sector in South Africa has focused on temporary workers' wages and benefits. Empirical research is limited: temporary employment services cannot be accurately identified in recent labour force surveys. In 2015, South Africa Revenue Services and the National Treasury made company and employee income tax data available which explicitly captures labour brokers and employee wages. We use this to examine whether there is a wage penalty for labour broker employees and, if so, its magnitude. We control for individual and time fixed effects. Such empirical evidence is important in debates on the sector's role in the South African labour market.

The genotoxicity and carcinogenicity data from in vitro and in vivo studies conducted during preclinical safety assessment of doxorubicin (DOXO), epirubicin (EPI) and idarubicin (IDA), are reviewed. The genotoxicity assays included a) gene mutation in Salmonella typhimurium with 5 tester strains; b) gene mutation in the V79 mammalian (lung) cell line; c) chromosome aberrations in human lymphocytes cultured in vitro; and d) chromosome aberrations in mouse bone marrow cells after intravenous (i.v.) administration in vivo. The long-term toxicity studies in the rat included a) single dose administration (3 mg/kg DOXO, 3.6 EPI and 0.75 IDA) to female rats of two different age groups, i.e. younger (7 weeks old at dosing) and older (13 weeks old), followed by one-year observation; and b) multiple dose administration to male and female rats (7 weeks old at dosing), consisting of i.v. administration of 0.25, 0.5 and 1 mg/kg DOXO or EPI and 0.06, 0.125 and 0.25 mg/kg IDA, once every 3 weeks for 10 cycles, followed by 18 months of observation. The genotoxicity studies revealed activity in gene mutation assays in bacterial and mammalian cells, and in chromosome aberration assays in human lymphocytes in vitro and in mouse bone marrow in vivo. In the two long-term studies in the rat, only mammary tumors were present. This finding was expected and, according to the literature, can be considered as species specific and not directly compound-related. The lack of tumor induction at the usual target organs for DNA reactive compounds, which are almost the same as those considered as target organs in anthracycline-exposed animals, indicates that the type and the extent of DNA damage precludes stimulation for proliferation and induction of neoplasia. Although an epigenetic mechanism can be hypothesized, support for such a mechanism is lacking.